Pharmaceutical CDMO 2.0 Market
完整報告名稱與涵蓋範圍
Pharmaceutical CDMO 2.0 Market Share & Trends Analysis Report, By Business Model (Tech-Enabled CDMOs, On-Demand/POD Manufacturing, End-to-End Integrated, Niche-Focused, Sustainability-Driven, Hybrid Partnerships), By Service Type (Development Services, Manufacturing Services, Specialty Services), By Drug Type (Small Molecules, Biologics, Advanced Therapies), By Therapeutic Area, By End User, By Region, and Segment Forecasts, 2025-2034
報告摘要
Industry analysis indicates the Pharmaceutical CDMO 2.0 Market globally will develop at a 8.4% CAGR during 2025–2034.
Pharmaceutical CDMO 2.0 encompasses the next generation of contract development and manufacturing organizations (cdmos) that go beyond traditional manufacturing services by offering integrated, technolo. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is underpinned by a convergence of factors: rising awareness among end users, continuous product innovation, and the rising emphasis on efficiency and sustainability within the healthcare sector.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region set to deliver the strongest growth trajectory through the forecast period, underpinned by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Pharmaceutical CDMO 2.0 Market Snapshot
Chapter 4. Global Pharmaceutical CDMO 2.0 Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Pharmaceutical CDMO 2.0 Market Industry Trends
4.10. Global Pharmaceutical CDMO 2.0 Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Pharmaceutical CDMO 2.0 Market Segmentation 1: By Business Model, Estimates & Trend Analysis
5.1. Market Share by Business Model, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Business Model:
5.2.1. Tech-Enabled CDMOs
5.2.1.1. AI/ML-Driven Development
5.2.1.2. Digital Twin Simulations
5.2.1.3. Blockchain Supply Chains
5.2.1.4. Robotic Process Automation
5.2.2. On-Demand/POD Manufacturing
5.2.2.1. Modular Facilities
5.2.2.2. Point-of-Demand (POD) Hubs
5.2.2.3. Just-in-Time Production
5.2.3. End-to-End Integrated
5.2.3.1. Full-Service Biologics Platforms
5.2.3.2. ATMP (Cell/Gene Therapy) Vertical Integration
5.2.4. Niche-Focused
5.2.4.1. Viral Vector Manufacturing
5.2.4.2. mRNA/LNP Production
5.2.4.3. CRISPR & Cell Therapy
5.2.5. Sustainability-Driven
5.2.5.1. Green Chemistry CDMOs
5.2.5.2. Carbon-Neutral Facilities
5.2.5.3. Zero-Waste Manufacturing
5.2.6. Hybrid Partnerships
5.2.6.1. Equity-Based Deals
5.2.6.2. Co-Location Models
5.2.6.3. Revenue-Sharing Agreements
Chapter 6. Pharmaceutical CDMO 2.0 Market Segmentation 2: By Service Type, Estimates & Trend Analysis
6.1. Market Share by Service Type, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Service Type:
6.2.1. Development Services
6.2.2. Manufacturing Services
6.2.3. Specialty Services
Chapter 7. Pharmaceutical CDMO 2.0 Market Segmentation 3: By End-User Industry, Estimates & Trend Analysis
7.1. Market Share by End-User Industry, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User Industry:
7.2.1. Big Pharma
7.2.2. Biotech Startups
7.2.3. Virtual Pharma
7.2.4. Government/NGOs
Chapter 8. Offline Pharmaceutical CDMO 2.0 Market Segmentation 4: By Drug Type, Estimates & Trend Analysis
8.1. Market Share by Drug Type, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Type:
8.2.1. Small Molecules
8.2.2. Biologics (mAbs, Vaccines, Recombinant Proteins)
8.2.3. Advanced Therapies (Cell/Gene, mRNA, RNAi)
Chapter 9. Pharmaceutical CDMO 2.0 Market Segmentation 5: By Therapeutic Area, Estimates & Trend Analysis
9.1. Market Share by Therapeutic Area, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapeutic Area:
9.2.1. Oncology
9.2.2. Rare/Orphan Diseases
9.2.3. Infectious Diseases
9.2.4. Autoimmune & CNS Disorders
9.2.5. Others
Chapter 10. Pharmaceutical CDMO 2.0 Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Pharmaceutical CDMO 2.0 Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Business Model, 2021-2034
10.2.3. North America Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.2.4. North America Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.2.5. North America Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
10.2.6. North America Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.3. Europe
10.3.1. Europe Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Business Model, 2021-2034
10.3.3. Europe Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.3.4. Europe Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.3.5. Europe Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
10.3.6. Europe Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Business Model, 2021-2034
10.4.3. Asia Pacific Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.4.4. Asia Pacific Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts Drug Type, 2021-2034
10.4.5. Asia Pacific Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.5. Latin America
10.5.1. Latin America Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Business Model, 2021-2034
10.5.3. Latin America Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.5.4. Latin America Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.5.5. Latin America Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
10.5.6. Latin America Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Business Model, 2021-2034
10.6.3. Middle East & Africa Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.6.4. Middle East & Africa Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.6.5. Middle East & Africa Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
10.6.6. Middle East & Africa Pharmaceutical CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Lonza
11.2.1.1. Business Overview
11.2.1.2. Key Business Model/Service Overview
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. WuXi AppTec / WuXi Biologics
11.2.3. Thermo Fisher Scientific (Patheon + Brammer Bio)
11.2.4. Catalent
11.2.5. Samsung Biologics
11.2.6. Recipharm
11.2.7. Fujifilm Diosynth
11.2.8. Oxford Biomedica
11.2.9. AGC Biologics
11.2.10. Charles River Labs
11.2.11. Siegfried
11.2.12. Aenova
11.2.13. Piramal Pharma Solutions
11.2.14. Hitachi Chemical (now part of AGC)
11.2.15. Cytiva
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們